Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Freek R. van ‘t Land

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0009-1990-9672; OpenAlex author ID A5054427267. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 2 papers · 2024: 4 papers · 2025: 3 papers · 2026: 3 papers

Papers 16

  1. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  2. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… First author DOI 10.1093/bjsopen/zrag058↗
  3. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  4. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. First author DOI 10.1038/s41467-025-66092-1↗
  5. Quality of Life in Patients with Locally Advanced Pancreatic Cancer During Stereotactic Radiotherapy Combined with Heat-Killed Mycobacterium Obuense Vaccinatio… First author DOI 10.1089/jpm.2024.0160↗
  6. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  7. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. Co-author DOI 10.1016/j.pan.2024.08.014↗
  8. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1200/jco.23.02585↗
  9. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  10. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  11. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-p… Co-author DOI 10.1016/j.radonc.2023.109541↗
  12. Increasing Systemic Immune-inflammation Index During Treatment in Patients With Advanced Pancreatic Cancer is Associated With Poor Survival: A Retrospective, M… Co-author DOI 10.1097/sla.0000000000005865↗
  13. Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. Co-author DOI 10.1007/s00520-021-06648-1↗
  14. Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastat… First author DOI 10.1136/bmjopen-2021-060431↗
  15. Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced P… Co-author DOI 10.3390/cancers14215299↗
  16. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1681↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 12 shared papers, 2021–2026 · strength 2.19
  2. Bas Groot Koerkamp · 6 shared papers, 2021–2026 · strength 1.04
  3. Marjolein Y.V. Homs · 5 shared papers, 2022–2026 · strength 0.91
  4. Joost J.M.E. Nuyttens · 3 shared papers, 2022–2026 · strength 0.51
  5. Marcella Willemsen · 3 shared papers, 2022–2025 · strength 0.49
  6. Michail Doukas · 3 shared papers, 2021–2025 · strength 0.49
  7. Laura Schafthuizen · 2 shared papers, 2022–2025 · strength 0.48
  8. Izaak Quintus Molenaar · 2 shared papers, 2026 · strength 0.40
  9. Leonard W. F. Seelen · 2 shared papers, 2026 · strength 0.40
  10. Thomas F. Stoop · 2 shared papers, 2026 · strength 0.40
  11. Roeland F. de Wilde · 2 shared papers, 2026 · strength 0.40
  12. Hjalmar C. van Santvoort · 2 shared papers, 2026 · strength 0.40
  13. Marc G. Besselink · 2 shared papers, 2026 · strength 0.40
  14. Casper W.F. van Eijck · 2 shared papers, 2024–2025 · strength 0.36
  15. Bert A. Bonsing · 2 shared papers, 2023 · strength 0.33
  16. Eveline E. Vietsch · 2 shared papers, 2021–2024 · strength 0.31
  17. Sai Ping Lau · 2 shared papers, 2022 · strength 0.30
  18. Fleur van der Sijde · 2 shared papers, 2021–2022 · strength 0.30
  19. Lois A. Daamen · 1 shared paper, 2026 · strength 0.22
  20. Johanna W. Wilmink · 1 shared paper, 2026 · strength 0.22
  21. Vincent Erwin de Meijer · 1 shared paper, 2026 · strength 0.22
  22. Sebastiaan Festen · 1 shared paper, 2026 · strength 0.22
  23. Ignace H. J. T. de Hingh · 1 shared paper, 2026 · strength 0.22
  24. Martijn W.J. Stommel · 1 shared paper, 2026 · strength 0.22
  25. T Sugawara · 1 shared paper, 2026 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.